Premier Biomedical Releases Anti-CTLA4 Market Study
Published: Jun 17, 2014
EL PASO, Texas--(BUSINESS WIRE)--Premier Biomedical Inc. (OTCBB: BIEI), a biopharmaceutical company focused on developing and commercializing innovative immune system manipulation therapies for breast cancer, as well as potential novel therapies for Alzheimer’s disease, multiple sclerosis (“MS”), and traumatic brain injury (“TBI”), today announced the release of a market study conducted by Penn Biotech Group Healthcare Consulting (“PBG”) discussing its breast cancer treatment.
Help employers find you! Check out all the jobs and post your resume.